Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced the Company will participate in a presentation and
panel discussion at the upcoming RNA Leaders annual meeting, being
held September 4-5, 2024, in San Diego, CA. The Company’s
presentations will focus on the use of enzymes to drive the
scalable and cost-effective manufacture of short inhibitory
ribonucleic acid (siRNA) duplexes.
During a keynote panel presentation, Stefan
Lutz, PhD, Codexis Senior Vice President of Research, in addition
to other RNA industry leaders, will discuss how the
biopharmaceutical industry is developing new solutions to advance
RNA manufacturing, address production capacities and establish new
approaches to streamline clinical trials and standardize
protocols.
The Company’s second presentation will focus on
ligation, which enables the joining of siRNA fragments to generate
full-length siRNA duplexes. This approach reduces the overall costs
of siRNA manufacturing by leveraging the inherent benefits of short
fragment synthesis, including higher yield and increased purity.
Codexis recently launched its double-stranded RNA ligase screening
and optimization services, and the Company’s presentation will
demonstrate improvements across key ligase attributes critical for
siRNA manufacturing utilizing its Enzyme Catalyzed Oligonucleotide
(ECO) Synthesis™ manufacturing platform. These include high
catalytic activity at high substrate loading, as well as improved
performance on challenging sequences and modification near ligation
junctions. Additionally, improvements in manufacturability of
double-stranded RNA ligases are expected to result in a more
reliable and scalable enzyme supply.
Attendees of the conference may visit with the
Codexis team at Booth #9 in the exhibition hall. Appointments may
be made in advance by clicking here.
Presentation Details
Keynote Panel: Scaling RNA Therapies to Deliver
on the Promise of Precision MedicineDate:
Wednesday, September 4, 2024Time: 10:15 – 10:55 am
Pacific Daylight Time (PDT)Location: San Diego
Convention Center, San Diego, CACodexis Speaker:
Stefan Lutz, PhD, Senior Vice President of Research
Presentation Title: Cost-effective
Manufacturing of siRNA Duplexes at High Yield and Purity Using
Engineered Double-stranded RNA LigasesDate:
Wednesday, September 4, 2024Time: 11:45 am – 12:10
pm Pacific Daylight Time (PDT)Location: San Diego
Convention Center, San Diego, CACodexis Speaker:
Mathew Miller, PhD, Director, Life Science & RNA Technology
About RNAi Therapeutics Manufacturing
Ribonucleic acid (RNA) as a therapeutic modality
has gained tremendous traction in recent years with the growing
number of messenger RNA (mRNA) vaccines and small interfering RNA
(siRNA) candidates advancing in clinical studies. However,
large-scale production of RNA interference (RNAi) therapeutics
using traditional chemical synthesis faces complex challenges in
nucleic acid quality and quantity, as well as overall economics.
With over 450 RNAi therapies currently in clinical development,
including more than 40 assets in Phase 2 and Phase 3 clinical
trials targeting disease indications impacting millions of
patients, RNAi therapeutic demand is projected to outpace current
production capabilities by the end of the decade.
About the ECO Synthesis™ Manufacturing
Platform
Codexis’ proprietary Enzyme Catalyzed
Oligonucleotide (ECO) Synthesis™ manufacturing platform is being
designed to address these scalability and cost limitations by
potentially enabling the commercial-scale manufacture of RNAi
therapeutics through an enzymatic route. The Company presented
groundbreaking data at the TIDES USA 2024 annual meeting
demonstrating the enzymatic synthesis of a full-length sense strand
of the oligonucleotide lumasiran, a commercially available siRNA
therapeutic, as well as shorter sense strand fragments of a second
siRNA therapeutic asset, givosiran. The data demonstrate that
Codexis consistently achieved coupling efficiency greater than 98%,
which is equivalent to what is seen with phosphoramidite chemistry;
executed the enzymatic addition of a conjugation moiety to the
lumasiran strand; and confirmed the lack of notable impurities
typically observed in oligonucleotide synthesis via phosphoramidite
chemistry. A recording of the presentation, along with slides and
the data press release, can be found on the Codexis corporate
website.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® technology platform to
discover, develop and enhance novel, high-performance enzymes and
other classes of proteins. Codexis enzymes solve for real-world
challenges associated with small molecule pharmaceuticals
manufacturing and nucleic acid synthesis. The Company is currently
developing its proprietary ECO Synthesis™ manufacturing platform to
enable the scaled manufacture of RNAi therapeutics through an
enzymatic route. Codexis’ unique enzymes can drive improvements
such as higher yields, reduced energy usage and waste generation,
improved efficiency in manufacturing and greater sensitivity in
genomic and diagnostic applications. For more information,
visit https://www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “suggest,” “target,” “on track,” “will,” “would”
and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or
other comparable terminology. To the extent that statements
contained in this press release are not descriptions of historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management, including, but not limited
to, the ability of an enzymatic oligonucleotide synthesis process
to complement or replace traditional chemical synthesis; the
potential of the Company’s ECO Synthesis™ platform and
double-stranded RNA (dsRNA) ligase screening and optimization
services to create value for Codexis and its customers by enabling
commercial-scale manufacture of RNAi therapeutics; other
anticipated technical and commercial milestones related to the ECO
Synthesis™ platform and the dsRNA ligase program, and public
announcements related thereto; potential details and features of
the ECO Synthesis™ platform such as it being scalable and able to
reduce manufacturing costs, as well as having higher purity and
yield than existing methods; and the future demand for RNAi
therapeutics. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results
include, among others: Codexis’ dependence on its licensees and
collaborators; if any of its collaborators terminate their
development programs under their respective license agreements with
Codexis; Codexis may need additional capital in the future in order
to expand its business; if Codexis is unable to successfully
develop new technology such as its ECO Synthesis™ manufacturing
platform and dsRNA ligase; Codexis’ dependence on a limited number
of products and customers, and potential adverse effects to
Codexis’ business if its customers’ products are not received well
in the markets; whether the end markets for Codexis’ customers’
products develop and remain viable; if Codexis is unable to develop
and commercialize new products for its target markets; whether the
end markets for Codexis’ customers’ products develop and remain
viable; if competitors and potential competitors who have greater
resources and experience than Codexis develop products and
technologies that make Codexis’ products and technologies obsolete;
Codexis’ ability to comply with debt covenants under its loan
facility; if Codexis is unable to accurately forecast financial and
operational performance; and market and economic conditions may
negatively impact Codexis business, financial condition and share
price. Additional information about factors that could materially
affect actual results can be found in Codexis’ Annual Report on
Form 10-K for the year ended December 31, 2023 filed with the
Securities and Exchange Commission (“SEC”) on February 28, 2024 and
in Codexis’ Quarterly Report on Form 10-Q for the quarter ended
June 30, 2024 filed with the SEC on August 8, 2024, including under
the caption “Risk Factors,” and in Codexis’ other periodic reports
filed with the SEC. Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Oct 2023 to Oct 2024